Markets
Top tech stocks for growth
(CSA Archive/Getty Images)

BMO: Here’s where to look for smoking growth in tech

Tech has been a massive outperformer off the market bottom.

Large-cap tech shares have ripped since the market’s April 8 bottom, with the Nasdaq 100 (Invesco QQQ Trust) up roughly 27% compared to the S&P 500’s (SPDR S&P 500 ETF) roughly 20% gain.

BMO equity analyst Brian Belski has been overweight on tech for a while, but he suggests that, going forward, tech’s performance will be dominated less by a sector-wide, knee-jerk recovery from the early April tariff panics than by the performance of certain individual shares. In a note published today, he wrote:

“We advocate for a highly selective approach to sector positioning. While we still prefer slightly smaller stocks within the sector with GARP [growth at a reasonable price] attributes as our preferred strategy, we thought it would be helpful to highlight some alternative selection approaches this time around... Specifically, we decided to “decompose” [growth at a reasonable price] and identify what we would view as the growth and value opportunities within the sector at both the industry and individual stock levels.”

Belski ginned up some helpful tables that break out tech companies with the highest expectations for earnings growth — he looks at near-term and long-term earnings-per-share expectations — as well as expected near-term return on equity, a key measure of how well companies use invested dollars to produce profits, combining all those measures to come up with a ranking.

Here are the top 10, which include retail investor favorites like Palantir and Nvidia as well as some less sexy companies, such as Seagate Technology. The maker of hard disk drives has jumped nearly 100% since the market’s April 8 low.

More Markets

See all Markets
markets

Tesla delivered 358,023 vehicles in Q1, short of expectations

Ahead of its first-quarter earnings later this month, Tesla on Thursday announced that it delivered 358,023 vehicles in the quarter.

Analysts polled by FactSet had expected 380,500 vehicle deliveries in the first quarter this year, while Tesla last month released its own company-compiled Wall Street consensus estimate — something it began in the fourth quarter of 2025 — of 365,645 vehicles.

Shares extended losses in premarket trading on Thursday, falling more than 4%.

The figure is still up from the same quarter last year, when Tesla delivered fewer than 337,000 vehicles amid intensifying competition in China and flailing public perception over CEO Elon Musk’s involvement with the Trump administration.

As of 3 p.m. ET on Wednesday, event contract odds held a slightly less optimistic view than the broader analyst community, but a sunnier view than the figure Tesla put forward. 52% of traders predicted Tesla’s Q1 deliveries would come in at more than 360,000, 40% thought the figure would be higher than 370,000, and 15% estimated it would be higher than 380,000.

(Event contracts are offered through Robinhood Derivatives, LLC — probabilities referenced or sourced from KalshiEx LLC or ForecastEx LLC.)

markets

Globalstar surges after FT reports that Amazon is in talks to buy the satellite group

Globalstar is up 11% in premarket trading on Thursday on reports that Amazon is in talks to buy the satellite company, in a push to take on Elon Musks SpaceX. The two companies are currently negotiating the details of a potential deal after lengthy talks, the Financial Times reported, citing people familiar with the matter.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

Amazon has ambitions to compete with SpaceX to provide satellite-based internet access anywhere on the planet — a market thats dominated by Starlink at the moment and a key pillar of the eye-watering $1 trillion valuation that SpaceX is seeking in its IPO, which it has just confidentially filed for.

Indeed, Amazon has been signing deals with airlines and doubling down on investing in its internet constellation lately, with plans to increase its ~200 satellites in orbit to about 700 by the middle of 2026 — still a fraction compared to SpaceX’s mega constellation, which has some 10,000 active satellites.

But Amazon’s not the only Big Tech giant with an interest in Globalstar. Back in 2024, Apple invested $1.5 billion for a 20% stake in the company, necessitating a negotiation between Apple and Amazon for the latest deal talks to proceed, per the FT. SpaceX also reportedly had early talks with Globalstar, Bloomberg reported last October.

Globalstars stock has been up ~230% in the past year, pushing its value to some $8.8 billion as of yesterday’s close.

markets

FDA clarifies stricter stance on GLP-1 compounding: Reuters

The Food and Drug Administration reiterated its increasingly strict stance on compounded versions of GLP-1s, Reuters reported Wednesday.

The FDA said that outside of drug shortages, “routine production” of copycat drugs is not allowed. Producing the compounded versions could now “prompt enforcement action,” Reuters reported.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Hims & Hers, which has historically been one of the largest sellers of copycat GLP-1s, fell more than 4% on Wednesday and slipped further in premarket trading on Thursday.

Hims attracted FDA scrutiny in February when it launched a copy of Novo Nordisk’s new GLP-1 pill. At the time, the FDA said it would take “decisive steps” to restrict GLP-1 compounding in a statement that specifically called out Hims.

After a bitter spat with Novo, which makes Ozempic and Wegovy, Hims entered a pact with the drugmaker in which it agreed not to market compounded GLP-1s.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, Robinhood Derivatives, LLC, or Robinhood Money, LLC. Futures and event contracts are offered through Robinhood Derivatives, LLC.